Although there was no harm, data and safety monitoring board found the drug ‘very unlikely to be beneficial’
MONDAY, June 22, 2020 (HealthDay News) — The National Institutes of Health announced Saturday that a clinical trial evaluating hydroxychloroquine for the treatment of COVID-19 has been stopped because the drug likely provides no benefit.
The Outcomes Related to COVID-19 treated with hydroxychloroquine among In-patients with symptomatic Disease (ORCHID) study was a blinded, placebo-controlled randomized clinical trial that intended to enroll more than 500 hospitalized COVID-19 patients. Participants were first enrolled in April at Vanderbilt University Medical Center in Nashville, Tennessee, and when the study was stopped, more than 470 patients had been enrolled.
Late Friday, a data and safety monitoring board determined that although the drug caused no harm, it was “very unlikely to be beneficial to hospitalized patients with COVID-19,” the NIH wrote in a media advisory.
All trial participants had received clinical care, and those randomly assigned to the experimental intervention also received hydroxychloroquine 400 mg twice daily for two doses on day 1 and then 200 mg twice daily on days 2 to 5. The NIH said participants will now continue to receive standard of care and follow-up as indicated for their condition.
~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2 
Parts of the World Seeing New COVID-19 Variant 
Targeted Grant Terminations Have Affected 694 NIH Grants 
HHS, NIH Unveil Vaccine Initiative to Protect Against Future Pandemics 
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens 
AAP Releases Influenza Vaccine Recommendations for All Children 6 Months and Older 
Adverse Event Risk Not Up With Same Day COVID-19, Flu Vaccination 
